high dose ARA-C

DRUG2 trials

Sponsors

Prof. Dr. M. Dreyling (co-chairman), National Research Center for Hematology, Russia

Conditions

Acute Myeloid LeukemiaMantle Cell Lymphoma

Phase 3

Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

Prof. Dr. M. Dreyling (co-chairman)Mantle Cell Lymphoma

Start: 2009-05-09End: 2018-12-31Updated: 2017-03-07

Phase 4

3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia

National Research Center for Hematology, RussiaAcute Myeloid Leukemia

Start: 2010-01-31End: 2015-01-31Target: 245Updated: 2014-04-07

Related Papers

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

Leukemia2024-04-278 citations

Plasmapheresis Is an Effective Approach Preventing Clinically Significant Tumor Lysis Syndrome during Induction Therapy in AML Patients with Hyperleukocytosis

Blood2014-12-06

Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial

Blood2014-12-06